进展性肺纤维化的研究进展
Research Progress of Progressive Pulmonary Fibrosis
DOI: 10.12677/ACM.2024.141039, PDF,   
作者: 庄 凯：内蒙古医科大学研究生院，内蒙古 呼和浩特；高俊珍*：内蒙古医科大学附属医院呼吸与危重症医学科，内蒙古 呼和浩特
关键词: 进展性肺纤维化；间质性肺疾病；Progressive Pulmonary Fibrosis； Interstitial Lung Disease
摘要: 间质性肺疾病(interstitial lung diseases, ILD)中一部分患者早期即可出现呼吸困难、血氧饱和度下降，在影像学上肺纤维化呈进行性加重，这类病人治疗反应不佳，最终因呼吸衰竭早期死亡。2022年ATS/ERS/JRS/ALAT提出了进展性肺纤维化(progressive pulmonary fibrosis, PPF)这一概念用于囊括除IPF以外的纤维化进行性加重的ILD。PPF为新的分类方法，目前流行病学、临床特征、发生发展的规律、抗炎、抗纤维化治疗反应等均不清晰，值得我们深入研究。本文将对PPF的研究进展作一综述，以期促进对PPF的认识。
Abstract: Some patients with interstitial lung diseases (ILD) may experience respiratory difficulties and de-creased blood oxygen saturation in the early stages, and pulmonary fibrosis worsens in imaging. These patients have poor treatment response and ultimately die from respiratory failure in the early stages. In 2022, ATS/ERS/JRS/ALAT proposed the concept of progressive pulmonary fibrosis (PPF) to encompass ILD with progressive fibrosis other than IPF. PPF is a new classification method that is currently unclear in terms of epidemiology, clinical characteristics, occurrence and devel-opment patterns, anti-inflammatory and anti fibrotic treatment responses, and is worthy of further research. This article will provide a review of the research progress on PPF in order to promote un-derstanding of PPF.
文章引用：庄凯, 高俊珍. 进展性肺纤维化的研究进展[J]. 临床医学进展, 2024, 14(1): 271-277. https://doi.org/10.12677/ACM.2024.141039

参考文献

[1] American Thoracic Society and European Respiratory Society (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) Was Adopted by the ATS Board of Directors, June 2001 and by the ERS Executive Committee, June 2001. American Journal of Respiratory and Critical Care Medicine, 165, 277-304.
[2] 牟相, 赵明栋. 进展性纤维化性间质性肺疾病流行现状及危险因素的研究进展[J]. 临床肺科杂志, 2023, 28(3): 412-415.
[3] Wells, A.U., Brown, K.K., Flaherty, K.R., Kolb, M., Thannickal, V.J. and IPF Consensus Working Group (2018) What’s in a Name? That Which We Call IPF, by Any Other Name Would Act the Same. European Respiratory Journal, 51, Article ID: 1800692. [Google Scholar] [CrossRef] [PubMed]
[4] 白子娜, 李幸彬. 吡非尼酮治疗特发性肺纤维化的研究进展[J]. 中国新药与临床杂志, 2023, 42(9): 560-565. [Google Scholar] [CrossRef] 
[5] Raghu, G., Remy-Jardin, M., Richeldi, L., et al. (2022) Idi-opathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 205, e18-e47. [Google Scholar] [CrossRef] 
[6] Flaherty, K.R., Wells, A.U., Cottin, V., et al. (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. The New England Journal of Medicine, 381, 1718-1727. [Google Scholar] [CrossRef] 
[7] Behr, J., Neuser, P., Prasse, A., et al. (2017) Exploring Efficacy and Safety of Oral Pirfenidone for Progressive, Non-IPF Lung Fibrosis (RELIEF)—A Randomized, Double-Blind, Place-bo-Controlled, Parallel Group, Multi-Center, Phase II Trial. BMC Pulmonary Medicine, 17, Article No. 122. [Google Scholar] [CrossRef] [PubMed]
[8] Maher, T.M., Corte, T.J., Fischer, A., et al. (2020) Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: A Double-Blind, Randomised, Place-bo-Controlled, Phase 2 Trial. The Lancet Respiratory Medicine, 8, 147-157. [Google Scholar] [CrossRef] 
[9] Reiseter, S., Gunnarsson, R., Mogens Aaløkken, T., et al. (2018) Progression and Mortality of Interstitial Lung Disease in Mixed Connective Tissue Disease: A Long-Term Ob-servational Nationwide Cohort Study. Rheumatology (Oxford), 57, 255-262. [Google Scholar] [CrossRef] [PubMed]
[10] Zamora-Legoff, J.A., Krause, M.L., Crowson, C.S., Ryu, J.H. and Matteson, E.L. (2017) Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis & Rheumatology, 69, 542-549. [Google Scholar] [CrossRef] [PubMed]
[11] Nasser, M., Larrieu, S., Si-Mohamed, S., et al. (2021) Progressive Fibrosing Interstitial Lung Disease: A Clinical Cohort (the PROGRESS Study). European Respiratory Journal, 57, Article ID: 2002718. [Google Scholar] [CrossRef] [PubMed]
[12] Hambly, N., Farooqi, M.M., Dvorkin-Gheva, A., et al. (2022) Prevalence and Characteristics of Progressive Fibrosing Interstitial Lung Disease in a Prospective Registry. European Respiratory Journal, 60, Article ID: 2102571. [Google Scholar] [CrossRef] [PubMed]
[13] Adegunsoye, A., Oldham, J.M., Bellam, S.K., et al. (2019) Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Di-verse Interstitial Lung Diseases. Annals of the American Thoracic Society, 16, 580-588. [Google Scholar] [CrossRef] 
[14] Walsh, S.L., Sverzellati, N., Devaraj, A., Keir, G.J., Wells, A.U. and Hansell, D.M. (2014) Connective Tissue Disease Related Fibrotic Lung Disease: High Resolution Computed Tomographic and Pulmonary Function Indices as Prognostic Determinants. Thorax, 69, 216-222. [Google Scholar] [CrossRef] [PubMed]
[15] Kim, H.C., Choi, K.H., Jacob, J. and Song, J.W. (2020) Prog-nostic Role of Blood KL-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease. PLOS ONE, 15, e0229997. [Google Scholar] [CrossRef] [PubMed]
[16] Açıkgöz, S.K., Açıkgöz, E., Şensoy, B., Topal, S. and Aydoğdu, S. (2016) Monocyte to High-Density Lipoprotein Cholesterol Ratio Is Predictive of In-Hospital and Five-Year Mortality in ST-Segment Elevation Myocardial Infarction. Cardiology Journal, 23, 505-512.
[17] Chan, A.S. and Rout, A. (2020) Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. Journal of Clinical Medicine Re-search, 12, 448-453. [Google Scholar] [CrossRef] [PubMed]
[18] Xu, Y., He, H., Zang, Y., et al. (2022) Systemic In-flammation Response Index (SIRI) as a Novel Biomarker in Patients with Rheumatoid Arthritis: A Multi-Center Retro-spective Study. Clinical Rheumatology, 41, 1989-2000. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, Y., Cai, J., Zhang, M. and Yan, X. (2022) Prognostic Role of NLR, PLR and MHR in Patients with Idiopathic Pulmonary Fibrosis. Frontiers in Immunology, 13, Article ID: 882217. [Google Scholar] [CrossRef] [PubMed]
[20] Xue, M., Guo, Z., Cai, C., Sun, B. and Wang, H. (2019) Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia. Respiration, 98, 534-545. [Google Scholar] [CrossRef] [PubMed]
[21] Inoue, Y., Kaner, R.J., Guiot, J., et al. (2020) Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. Chest, 158, 646-659. [Google Scholar] [CrossRef] [PubMed]
[22] 于娜, 王玮. 间质性肺疾病的治疗进展[J]. 临床内科杂志, 2022, 39(10): 656-658.
[23] Rajan, S.K., Cottin, V., Dhar, R., et al. (2023) Progressive Pulmonary Fibrosis: An Expert Group Consensus Statement. European Respiratory Journal, 61, Article ID: 2103187. [Google Scholar] [CrossRef] [PubMed]
[24] Dawson, J.K., Quah, E., Earnshaw, B., Amoasii, C., Mudawi, T. and Spencer, L.G. (2021) Does Methotrexate Cause Progressive Fibrotic Interstitial Lung Disease? A Systematic Re-view. Rheumatology International, 41, 1055-1064. [Google Scholar] [CrossRef] [PubMed]
[25] Kim, J.W., Chung, S.W., Pyo, J.Y., et al. (2023) Methotrexate, Leflunomide and Tacrolimus Use and the Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease. Rheumatology (Oxford), 62, 2377-2385. [Google Scholar] [CrossRef] [PubMed]
[26] Baughman, R.P. and Grutters, J.C. (2015) New Treatment Strategies for Pulmonary Sarcoidosis: Antimetabolites, Biological Drugs, and Other Treatment Approaches. The Lancet Respiratory Medicine, 3, 813-822. [Google Scholar] [CrossRef] 
[27] 王佳琦, 舒强. 吡非尼酮联合免疫抑制剂治疗结缔组织病相关肺间质性病变的研究进展[J]. 山东第一医科大学(山东省医学科学院)学报, 2022, 43(4): 304-310.
[28] 张凤芹, 窦欣然, 张惠兰. 新型冠状病毒感染后间质性肺疾病[J]. 中国实用内科杂志, 2023, 43(9): 714-717.
[29] 陈雨田, 丁楅森. 血管分泌因子调控肺再生与纤维化的机制研究进展[J]. 生物医学转化, 2023, 4(3): 25-31.
[30] Xu, Z., Li, H., Wen, F., et al. (2019) Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Advances in Therapy, 36, 621-631. [Google Scholar] [CrossRef] [PubMed]
[31] Ogura, T., Inoue, Y., Azuma, A., et al. (2023) Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Sur-veillance in Japan. Advances in Therapy, 40, 1474-1493. [Google Scholar] [CrossRef] [PubMed]
[32] Gagliardi, M., Berg, D.V., Heylen, C.E., et al. (2021) Real-Life Prevalence of Progressive Fibrosing Interstitial Lung Diseases. Scientific Reports, 11, Article No. 2398. [Google Scholar] [CrossRef] [PubMed]
[33] Khanna, D., Albera, C., Fischer, A., et al. (2016) An Open-Label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-Associated Interstitial Lung Disease: The LOTUSS Trial. The Journal of Rheumatology, 43, 1672-1679.

为你推荐